Cell Culture Market

The cell culture market is projected to reach USD 57.9 billion by 2029 from an estimated USD 30.9 billion in 2024, at a CAGR of 13.4% during the forecast period of 2024 to 2029.  Growth of the cell culture market can be attributed to factors such as the increasing focus and adoption of single use technologies like single use bioreactors, which offer advantages over methods. There is also a rising demand for therapeutics such as monoclonal antibodies, biosimilars and vaccines due to the increasing prevalence of diseases alongside the expanding biotechnology sector. However the high costs associated with cell biology research might impede market growth as it involves research and development into therapies like stem cell and gene therapies. It is crucial that the equipment, reagents and other products used in cell biology research maintain high quality to ensure accurate results.

Cell Culture Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Global Cell Culture Market Dynamics

DRIVER: Increasing fundings for cell-based research

Cell culture plays an important role in developing products to combat diseases such as cancer and cardiovascular conditions. Globally, significant research efforts supported by government and private organizations are focused on pioneering cell therapy solutions. For example, CellVovant, a company associated with the University of Bristol received USD 9.55 million (GBP 7.6 million) in seed funding in January 2021 to expedite the development of stem cell therapies. Furthermore, collaborations between private sectors are propelling progress; notable instances include support from organizations like the Ovarian Cancer Research Alliance and the European Research Council for exploring stem cell based treatments, for various illnesses. The cell therapy market is expected to experience growth due to the rising focus and investment for treating neurological and cardiovascular conditions.

RESTRAINT: High cost of cell biology research

Research on advanced therapies including stem cells and gene therapies in cell biology involves using advanced instruments and reagents to ensure accurate outcomes. The cost of cell biology research has surged significantly as the need for stringent regulatory compliance and quality control increases. Adopting microcarrier-based technologies for large-scale cell culture is challenged by the costly nature of this research as well as budgetary restrictions experienced by researchers and small-scale pharmaceutical companies. These financial constraints restrict possible adopters and consumers, therefore impeding the expansion of the cell culture industry. In cell analysis, similarly, the introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies has raised their dependability. However new technologies have also caused instruments to become quite more expensive.

OPPORTUNITY: Growth opportunities in emerging economies

Emerging countries such as India, China, and Brazil offer attractive opportunities for market players, owing to booming biopharmaceutical sectors, lower regulatory requirements, diverse healthcare markets, and support from the government. Particularly in pharmaceuticals, developing countries in the Asia Pacific have become the center of attention for companies looking for affordable manufacturing sites. To meet growing needs, especially for vaccines and antibiotics, pharmaceutical companies are increasingly outsourcing drug development efforts, hence driving the growth of cell culture in these developing nations. Driven by factors including the increasing need for innovative treatments, precision medicine, and technological developments including artificial intelligence and big data analytics, the Asia-Pacific region is poised for notable expansion with large investments in biotech.

CHALLENGE: Disposal of plastic consumables

Cell culture is an adaptive research methodology. However, it is mainly dependent on plastic consumables, and vast amounts of plastic waste are generated each year, negatively impacting the environment. Furthermore owing to their benefits—cost reduction, faster process development time, and reduced capital investments—biopharmaceutical businesses are progressively using single-use bioprocessing equipment and consumables. In cleaning, sterilization, and batch changeover time they also reduce utilities and water expenses. However, there are severe issues about the disposal of solid waste products with this alternative approach. Therefore, issues related to the disposal of plastic consumables could impact the growth of the market.

Global Cell Culture Ecosystem Analysis

The cell culture market ecosystem comprises raw material suppliers, cell culture product manufacturers, and end users such as pharmaceutical and biotechnology companies, research & academic institutes, hospitals & diagnostic laboratories, CROs, CDMOs, and cell banks. Cell culture products manufacturers provide consumables including media, reagents, sera, vessels, and accessories, and equipment such as bioreactors, storage equipment, and other equipment.

Cell Culture Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

The biopharmaceutical production segment dominated cell culture market in 2023.

Based on application, the cell culture market is segmented into five major segments, namely, biopharmaceutical production, diagnostics, tissue engineering & regenerative medicine, drug screening & development, and other applications. biopharmaceutical production, diagnostics, tissue engineering & regenerative medicine, drug screening & development, and other applications. Biopharmaceutical production segment is further categorized as monoclonal antibodies, vaccine production, and other therapeutic proteins. Tissue engineering & regenerative medicine segment is further divided based on cell and gene therapy, and others tissue engineering & regenerative medicine. In 2023, biopharmaceutical production segment dominated the market owing to rising approval and launches of monoclonal antibodies and biosimilars and increasing prevalence of infectious diseases.

The pharmaceutical & biotechnology companies segment dominated the cell culture market in 2023.

Based on end user, the cell culture market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and other end users. Growing demand for biopharmaceuticals and personalised medicine, developments in cell-based therapies and regenerative medicine, and the necessity of scalable and affordable manufacturing techniques are some factors contributing to the pharmaceutical and biotechnology companies segment holding the largest market share in the global market in 2023. Cell culture is used extensively in pharma and biotech companies investigating novel treatments and drugs. Moreover, biotechnology companies depend on cell culture to generate advanced therapeutic products like cell and gene treatments as well as biologics including vaccines, antibodies, and recombinant proteins.

North America was the largest regional market for the cell culture market in 2023.

The global cell culture market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest of cell culture market in 2023, followed by Europe and the Asia Pacific. Factors such as significant expenditure on R&D activities, presence of a well-established industry players, and growing demand for cell and gene therapies are responsible for the largest share of this segment.

Key Market Players

Key players in the cell culture market include Thermo  Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Caisson Labs (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US).

Scope of the Cell Culture Industry

This report categorizes the cell culture market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
  • Sera, Media, Reagents
    • Media
      • Serum-free media
      • Classical media & salts
      • Stem cell culture media
      • Chemically defined media
      • Specialty media
      • Other media
    • Reagents
      • Growth factors
      • Supplements
      • Buffers & chemicals
      • Cell dissociation reagents
      • Balanced salt solutions
      • Attachment & matrix factors
      • Antibiotics/Antimycotics
      • Cryoprotective Reagents
      • Contamination Detection Kits
      • Other cell culture reagents
    • Sera
      • Fetal Bovine sera
      • Adult Bovine sera
      • Other animal sera
  • Vessels
    • Cell factory systems/cell stacks
    • Roller/roux bottles
    • Flasks
    • Multiwall Plates
    • Petri dishes
• Equipment
  • Bioreactors
    • Conventional Bioreactors
    • Single Use Bioreactor
  • Storage Equipment
    • Refrigerators & freezers
    • Cryostorage systems
  • Other Equipment
    • Filtration systems
    • Cell counters
    • Carbon dioxide incubators
    • Centrifuges
    • Autoclaves
    • Microscopes
    • Biosafety cabinets
    • Other supporting equipment

By Application

• Biopharmaceutical Production
  • Monoclonal Antibody Production
  • Vaccine Production
  • Other Therapeutic Protein Production
• Diagnostics
• Tissue Engineering & Regenerative Medicine
  • Cell And Gene Therapy
  • Other Tissue Engineering and Regenerative Medicine Applications
• Drug Screening & Development
• Other Applications

By End User

• Pharmaceutical & Biotechnology Companies
• Hospitals And Diagnostic Laboratories
• Research & Academic Institutes
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East
  • GCC Countries
    • Saudi Arabia (KSA)
    • United Arab Emirates (UAE)
    • Rest of GCC Countries (RoGCC)
  • Rest of Middle East (RoME)
• Africa

Recent Developments of Cell Culture Industry:

• In September 2023, Thermo Fisher Scientific launched the Gibco CTS Detachable Dynabeads, a groundbreaking platform with an innovative active-release mechanism designed for the clinical and commercial operation of cell therapy manufacturing.
• In December 2023, Danaher acquired Abcam, a provider of validated antibodies, reagents, biomarkers, and assays crucial for drug discovery, life sciences research, and diagnostics. Within Danaher’s Life Sciences segment, Abcam will continue to operate independently, aligning with Danaher’s mission to advance disease understanding and expedite drug discovery.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst